Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems ...

Pfizer shares remain under pressure amid declining COVID vaccine demand, looming patent expirations, and delays in entering the GLP-1 weight-loss market. Meanwhile, Cadrenal Therapeutics gained ...

Tempo's Fact Check team verified this claim by interviewing epidemiologists and comparing it with various credible sources.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...

But Pfizer isn't dead money if you have a long-term view of investing. Here's why you might still want to buy it. Pfizer ...

That means in the absence of new, vaccine-evading coronavirus variants — a big if — next fall and winter could look a lot different in Canada in terms of the impact of COVID-19. Loading external pages ...

S&P 500 Q1 earnings surge 27.1% as Alphabet, Apple, Amazon beat forecasts. Meta falls on AI capex fears. 128 firms report ...

Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...